Distributor inventory
Voglibose 0.2 mg + Metformin (strength unknown)
Treatment of type 2 diabetes mellitus to improve post-meal and overall blood glucose control, usually when diet/exercise alone or single-drug therapy is insufficient.
Voglibose is an alpha-glucosidase inhibitor that delays breakdown and absorption of carbohydrates in the intestine, reducing post-meal glucose spikes. Metformin decreases hepatic glucose production and improves insulin sensitivity, helping lower fasting and overall blood glucose.
Oral tablet. Take exactly as prescribed. Voglibose-containing tablets are usually taken just before meals/with the first bite; metformin is generally taken with food to reduce stomach upset. Swallow whole with water; do not skip meals.
Common side effects of VOGLIDYN M 0.2 may include:
For type 2 diabetes only. Risk of low blood sugar increases when used with insulin or sulfonylureas—recognize symptoms and treat promptly. Metformin may rarely cause lactic acidosis; seek urgent care for rapid breathing, severe weakness, abdominal pain, or unusual sleepiness. Use caution/avoid in severe kidney impairment, severe liver disease, severe infection, dehydration, or hypoxia; kidney function monitoring is advised. Temporarily stop metformin around iodinated contrast procedures or major surgery as advised by doctor. Gastrointestinal side effects are common initially.
